Patent · US Active

Molecules with reduced effector function and extended half-lives, compositions, and uses thereof

US10011660B2 · kind B2 · utility

2Cited by

4References

47Claims

0Family size

Assignee

MedImmune Limited · US

Inventors

Ping Tsui · Gaithersburg, US
Martin Jack BORROK, III · Forest Park, US
William Dall'Acqua · Gaithersburg, US

Key dates

Filing date	Apr 17, 2013
Grant date	Jul 3, 2018
Priority date	—
Expiry date	Aug 16, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/71
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are polypeptides comprising a variant IgG Fc domain, wherein the polypeptides exhibit reduced or ablated effector functions (e.g., ADCC and/or CDC) and increased stability and plasma half-life compared to a parent polypeptide. Also provided are compositions, methods of treatment, and methods to diminish Fc-induced effector function in a parent polypeptide.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.